Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting

Clinical trial data will be updated in three presentations on lead drug candidates Linperlisib, a potent oral PI3Kδ inhibitor, demonstrated robust clinical activity with 70% ORR in relapsed or refractory Peripheral T-cell Lymphoma Linperlisib is demonstrated to be well-tolerated in a 78...

from PR Newswire: https://ift.tt/34L2yKb